Use of Muscarinic Agonists in the Treatment of Sjögren's Syndrome

This publication has 123 references indexed in Scilit:

• Immunological localization of m1–m5 muscarinic acetylcholine receptors in peripheral tissues and brain
  Published by Elsevier ,2002
• The selective muscarinic M1 agonist AF102B decreases levels of total A? in cerebrospinal fluid of patients with Alzheimer's disease
  Annals of Neurology, 2000
• Matrix metalloproteinase (MMP)-9 type IV collagenase/gelatinase implicated in the pathogenesis of Sjögren's syndrome
  Matrix Biology, 1998
• Investigation of Activation Markers Demonstrates Significant Overexpression of the Secretory Component on Salivary Glands Epithelial Cells in Sjögren's Syndrome
  Clinical Immunology and Immunopathology, 1996
• Genetically Programmed Development of Salivary Gland Abnormalities in the NOD (Nonobese Diabetic)-scidMouse in the Absence of Detectable Lymphocytic Infiltration: A Potential Trigger for Sialoadenitis of NOD Mice
  Clinical Immunology and Immunopathology, 1996
• Alterations in the Secretory Response of Non-obese Diabetic (NOD) Mice to Muscarinic Receptor Stimulation
  Clinical Immunology and Immunopathology, 1996
• Muscarinic acetylcholine receptors: Structural basis of ligand binding and G protein coupling
  Life Sciences, 1995
• Prevention of the acute graft-versus-host disease (GVHD) in rats by the immunomodulating drug leflunomide
  Annals of Hematology, 1994
• Discrete activation of transduction pathways associated with acetylcholine m1 receptor by several muscarinic ligands
  European Journal of Pharmacology: Molecular Pharmacology, 1994
• Sialogogic activities of SNI-2011 compared with those of pilocarpine and McN-A-343 in rat salivary glands: Identification of a potential therapeutic agent for treatment of Sjörgen's syndrome
  General Pharmacology: The Vascular System, 1994